Trung Tran, MD
Internal Medicine · Gretna, LANPI 1043638893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Dexcom, Inc. at 25.3% of the total. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1K
- Novo Nordisk$1K
- Lilly USA, LLC$917
- Abbott$476
- Insulet Corporation$291
- Amgen$259
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,685100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 29 | $1,443 |
| Novo Nordisk | 62 | $1,182 |
| Lilly USA, LLC | 42 | $917 |
| Abbott | 19 | $476 |
| Insulet Corporation | 8 | $291 |
| Amgen | 7 | $259 |
| Johnson & Johnson(2 entities) | 3 | $222 |
| Bayer | 8 | $171 |
| AstraZeneca | 10 | $160 |
| Sanofi-aventis U.S. LLC | 6 | $116 |
| Xeris Pharmaceuticals, Inc. | 3 | $69 |
| Ascendis Pharma Endocrinology Inc | 3 | $68 |
| Sequel Med Tech, LLC | 2 | $67 |
| Tandem Diabetes Care, Inc. | 2 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Amphastar Pharmaceuticals, Inc. | 2 | $47 |
| Corcept Therapeutics | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$705
- Ozempic$234
- Omnipod$141
- DEXCOM CGM$136
- DEXCOM G6 CGM SYSTEM$126
- EVENITY$125
- RYBELSUS$125
- INVOKANA$120
How this compares
$5,697 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 388 | $541,835 |
| MounjaroTirzepatide | 378 | $531,480 |
| TrulicityDulaglutide | 223 | $326,411 |
| JardianceEmpagliflozin | 194 | $215,836 |
| JanuviaSitagliptin Phosphate | 53 | $71,933 |
| ForteoTeriparatide | 12 | $57,196 |
| Novolog FlexpenInsulin Aspart | 181 | $48,821 |
| TradjentaLinagliptin | 39 | $43,741 |
| FiaspInsulin Aspart (Niacinamide) | 18 | $32,664 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $32,086 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $31,984 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 244 | $30,761 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $26,044 |
| Teriparatide | 13 | $23,995 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $22,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $917 | $918,639632 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,182 | $586,744448 claims |
| AstraZenecaFarxiga | $160 | $17,34718 claims |
| BayerKerendia | $171 | $16,32016 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $6,006439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Gretna
- Everett BrownGretna$71K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
- Bryan LebeanLafayette$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.